GlassScriptPhysician profile
Mrudula R Munagala
NPI 1124280789
$67,358.11
in general payments reported to CMS, 2019-2025
23 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $21K · 2021: $8,760 · 2022: $715 · 2023: $427 · 2024: $814 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.74 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $17,612.51 | 2019-2025 | Amvuttra, Onpattro |
| Sanofi Pasteur INC. | $13,528.45 | 2020-2021 | |
| Akcea Therapeutics, INC. | $13,136.00 | 2019-2021 | |
| United Therapeutics Corporation | $5,738.89 | 2019-2023 | Remodulin, Tyvaso, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $5,016.17 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $4,907.87 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Abbott Laboratories | $4,500.79 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $440.18 | 2019-2025 | |
| Boston Scientific Corporation | $415.93 | 2019-2025 | Sentinel, Avvigo Guidance System, Watchman Flx |
| Impulse Dynamics (USA) INC. | $273.18 | 2022-2024 | Optimizer |
| Medtronic Vascular, INC. | $264.95 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $223.37 | 2019-2022 | |
| Abiomed | $195.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $174.20 | 2019-2020 | |
| Cvrx, INC. | $165.85 | 2024 | Barostim Neo System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ancora Heart, INC. | $160.57 | 2023-2025 | Accucinch |
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| Amgen INC. | $133.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $101.36 | 2019-2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $90.00 | 2019-2023 | Camzyos |
| Nuwellis, INC. | $49.40 | 2019-2020 | |
| Sandoz INC. | $39.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.88 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mrudula Munagala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.